NNP
SUPN icon

Nachman Norwood & Parrott’s Supernus Pharmaceuticals SUPN Stock Holding History

Nachman Norwood & Parrott’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-195
Closed -$4K – 948
2020
Q3 		$4K Buy
+195
New +$4.43K ﹤0.01% 1010

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Nachman Norwood & Parrott's SUPN Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 195 shares — an estimated $4K sold.

Nachman Norwood & Parrott first reported a position in SUPN in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 195 Supernus Pharmaceuticals shares in Q4 2020, an estimated $4K.
  • Nachman Norwood & Parrott first reported a position in Supernus Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Supernus Pharmaceuticals position peaked at $4K in Q3 2020.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.